These results show that IKKα or IKKβ inhibition reduces lung cancer cell proliferation in vitro and pharmacological IKKβ targeting reduces lung cancer growth in vivo, supporting the hypothesis that IKK inhibition therapy will have clinical benefits in lung cancer as well as other cancers, particularly for patients with KRAS mutations and altered p53 activity. Here, KRAS is linked to lung carcinoma.